Nivolumab, marketed under the brand name Opdivo, is a pioneering PD-1 inhibitor immunotherapy that has transformed the treatment landscape for multiple cancer types. Since its FDA approval in 2014, nivolumab has become one of the most significant oncology drugs globally, with indications spanning melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, classical Hodgkin lymphoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, and more than 15 distinct oncology settings. For pharmaceutical suppliers, manufacturers, and distributors seeking to navigate the global nivolumab market, understanding the buyer landscape is essential. This comprehensive guide presents the most current Nivolumab global buyers list, analyzes purchasing patterns across key regions, and provides strategic intelligence…